Every Form 4 that Bolt Biotherapeutics, Inc. (BOLT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BOLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLT filings page.
Bolt Biotherapeutics director Laura Berner received a grant of stock options for 5,000 shares of common stock. The options have an exercise price of $4.43 per share and expire on June 9, 2036.
The award vests on the earlier of June 9, 2027 or the day immediately before the next annual meeting of stockholders, as long as she remains in continuous service until that date. The options will vest in full if there is a change in control of Bolt Biotherapeutics before then. This is an acquisition of derivative securities by grant, not an open-market stock purchase or sale.
Bolt Biotherapeutics director Kathleen LaPorte received a stock option grant for 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting, assuming continuous service. The option will vest in full if there is a change in control of Bolt Biotherapeutics.
Bolt Biotherapeutics director Jakob Dupont received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day before the next annual stockholder meeting, with full vesting upon a change in control, assuming continuous service.
Bolt Biotherapeutics director Brian O’Callaghan received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $4.43 per share and expire on June 9, 2036. Following this grant, he holds options on 5,000 shares.
The options will vest on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting, as long as he remains in continuous service. They also vest in full if there is a change in control of Bolt Biotherapeutics.
Bolt Biotherapeutics director Nicole Onetto received a grant of stock options for 5,000 shares of common stock. The options have an exercise price of $4.43 per share and were awarded as a compensation-related grant, not an open-market purchase.
The filing shows she now holds stock options covering 5,000 shares directly after this transaction. These options vest on the earlier of June 9, 2027 or the day immediately before Bolt Biotherapeutics’ next annual stockholder meeting, subject to her continued service. The options will vest in full if there is a change in control of the company.
Bolt Biotherapeutics President, CEO and CFO William P. Quinn reported two transactions in company securities. On December 5, 2025, he purchased 125 shares of common stock at $4.607 per share under the Employee Stock Purchase Plan, bringing his directly held common stock to 2,313 shares.
On January 28, 2026, he was granted an employee stock option for 20,000 shares of common stock at an exercise price of $6.71 per share, expiring on January 27, 2036. The option vests in 36 equal monthly installments, with 1/36th of the shares vesting after each month of continuous service following January 1, 2026.
Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer, Yonehiro Grant, received an employee stock option grant. On January 28, 2026, Grant was awarded options to purchase 10,000 shares of Bolt common stock at an exercise price of $6.71 per share, expiring January 27, 2036.
The options vest over time, so long as Grant continues providing services to Bolt. Starting from January 1, 2026, 1/36 of the options vest after each completed month of continuous service, until all 10,000 options are fully vested.
Bolt Biotherapeutics officer reports small share purchase and new option grant. Senior VP, Finance and PAO Sarah Nemec bought 125 shares of common stock on 12/05/2025 at $4.607 per share under the company’s Employee Stock Purchase Plan, bringing her direct holdings to 1,415 shares.
On 01/28/2026 she received an employee stock option for 8,000 shares at a $6.71 exercise price. This option is scheduled to vest in equal monthly installments, with 1/36 of the shares vesting after each month of continuous service following January 1, 2026, and expires on January 27, 2036.
A director of Bolt Biotherapeutics, Inc. reported cancelling previously granted director stock options and receiving new options with lower exercise prices.
On December 12, 2025, the director received new options to buy 2,500, 849, 1,000 and 1,100 shares of common stock at an exercise price of $5.44 per share, with expiration dates between September 2, 2034 and May 26, 2035. In each case, options with higher exercise prices ranging from $6.40 to $13.596 for the same number of shares and similar expiration dates were cancelled in exchange for the new options, some of which are fully vested and others subject to monthly or time-based vesting and full vesting upon a change in control.
Bolt Biotherapeutics, Inc. director reported stock option transactions dated 12/12/2025. The Form 4 shows several director stock options on common stock being canceled and replaced with new options that have a lower exercise price, as described in the footnotes.
New director stock options with exercise prices such as $5.44 per share cover grants expiring on 12/13/2031, 03/23/2032, 06/09/2032, 06/11/2033, 06/11/2034 and 05/26/2035. One option is fully vested and exercisable, while another for 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately before the next annual meeting of stockholders, and will vest in full upon a change in control, subject to the director’s continuous service.
Bolt Biotherapeutics, Inc. reported that one of its directors entered into several option transactions on 12/12/2025. The director cancelled previously granted stock options with higher exercise prices and received new director stock options with an exercise price of $5.44 per share for the same numbers of underlying common shares.
One option grant for 2,500 shares expiring in 2032 vests in equal monthly installments from December 14, 2022 until the third anniversary of that date, while other grants reported are already fully vested and exercisable. Another 1,100-share option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and certain of these options vest in full upon a change in control of the company.
A director of Bolt Biotherapeutics, Inc. reported multiple option transactions dated December 12, 2025 involving director stock options on Bolt common stock. The director canceled several existing stock options and received new director stock options over the same numbers of shares, with each exchange recorded as a disposal and a corresponding acquisition.
In each case, the existing option was canceled in exchange for a new option with a lower exercise price of $5.44. One new option covering 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the director’s continuous service, and will vest in full upon a change in control of Bolt Biotherapeutics.
Bolt Biotherapeutics, Inc. director reported multiple stock option changes dated December 12, 2025. The reporting person agreed to cancellation of existing director stock options that had higher exercise prices such as $180.2, $60.6, $39.8, $32.6, $15.364 and $6.4 in exchange for new options having a lower exercise price of $5.44 per share. These new options cover blocks of common stock, including 1,393 and 1,810 shares. One new option for 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and will vest in full upon a change in control of the company.
Bolt Biotherapeutics reported insider equity activity involving its Senior VP, Finance and PAO, with an earliest transaction date of 12/12/2025. The filing covers a series of employee stock options on common stock.
The executive agreed to cancel multiple existing stock options granted between 2020 and 2025 in exchange for new employee stock options with a lower exercise price of $5.44 per share, in blocks such as 1,236, 375, 600, 2,199, 6,699, 1,589, 2,499, 4,499 and 11,299 shares. Some replacement options vest in equal monthly installments of 1/36th of the shares, so long as the executive continues providing services, with vesting schedules beginning after dates including January 1, 2023, January 1, 2024, July 15, 2024 and January 1, 2025. At least one option is already fully vested and exercisable.
Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer adjusted multiple employee stock options on 12/12/2025. Existing options with higher exercise prices were cancelled, and new employee stock options with a $5.44 exercise price and the same share amounts and expiration dates were granted in exchange.
One of the new options is fully vested and exercisable. Several other new options vest in equal 1/36th installments each month after specified dates in 2023, 2024 and 2025, for so long as the reporting person continuously provides services to the company.
Bolt Biotherapeutics reported changes to a senior insider’s equity compensation on December 12, 2025. The reporting person is a director who also serves as President, CEO and CFO, and the transactions involve employee stock options to purchase common stock.
Several existing stock option grants with higher exercise prices were cancelled in exchange for new employee stock options with an exercise price of $5.44 per share. One of the options is fully vested and exercisable, while multiple new options vest in 36 monthly installments as long as the reporting person continues providing services, with vesting schedules starting from dates such as January 1, 2023, January 1, 2024, July 15, 2024, and January 1, 2025.
Bolt Biotherapeutics (BOLT) insider activity: the company’s Senior VP, Finance and PAO reported two transactions. On June 6, 2025, the officer purchased 125 shares of common stock at $5.492, acquired under the Employee Stock Purchase Plan. On October 22, 2025, the officer received 23,000 restricted stock units for no consideration; each RSU represents one share upon settlement and will vest in full on September 15, 2026, assuming continued employment. Following these transactions, direct beneficial ownership stands at 23,943 shares.
Bolt Biotherapeutics (BOLT) reported an insider equity award. The Chief Operating Officer received 30,000 restricted stock units for no consideration on 10/22/2025. Each RSU represents the right to receive one share of common stock at settlement.
The award will vest in full on September 15, 2026, assuming continued employment through that date. Following the reported transaction, the officer beneficially owned 38,918 shares of common stock, held directly.
Bolt Biotherapeutics (BOLT) disclosed insider equity activity by its President, CEO and CFO, William P. Quinn. On 10/22/2025, he acquired 40,000 restricted stock units (RSUs) for $0. Each RSU represents one share of common stock at settlement, and the award vests in full on September 15, 2026, assuming continued employment.
Earlier, on 06/06/2025, Quinn purchased 125 shares of common stock at $5.492 per share under the company’s Employee Stock Purchase Plan, which is exempt under Rule 16b-3(c). After the reported transactions, he beneficially owned 42,188 shares directly.